Events & Programs

Dana-Farber has played a pivotal role in the approval of over half of all FDA-approved cancer drugs in the past five years, including tovorafenib and revumenib in 2024. Still, many cancers remain hard to treat. Our physician-scientists are leading the way in developing next-generation therapies to bring hope to pediatric and adult patients worldwide. Watch as Scott Armstrong, MD, PhD, Alice Shaw, MD, PhD, and Emily Heikamp, MD, PhD, MSc, delve into Dana-Farber’s efforts to revolutionize cancer therapy, with a specific focus on rare and hard-to-treat cancers. Learn how Dana-Farber’s unique infrastructure and expertise helps to accelerate the translation of... More

At Dana-Farber Cancer Institute, we believe that skin color, income, and zip code should never determine health outcomes. Watch as Narjust Florez, MD, Associate Director of Dana Farber’s Cancer Care Equity Program, leads a discussion about the Institute’s efforts to translate research into clinical interventions that will reduce disparities in cancer outcomes. Leading clinicians and investigators in the fields of pediatric, breast, gastrointestinal, and thoracic oncology discuss how they are working to ensure that all patients can benefit from lifesaving advancements at Dana-Farber and beyond. Panelists include Kira Bona, MD, MPH, Rachel Freedman, MD, MPH, and Nadine McCleary, MD, MPH.